BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 2020;14:351-360. [DOI: 10.1093/ecco-jcc/jjz152] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Reiss Z, Rob F, Kolar M, Schierova D, Kreisinger J, Jackova Z, Roubalova R, Coufal S, Mihula M, Thon T, Bajer L, Novakova M, Vasatko M, Kostovcikova K, Galanova N, Lukas M, Kverka M, Tresnak Hercogova J, Tlaskalova-Hogenova H, Jiraskova Zakostelska Z. Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy. Front Cell Infect Microbiol 2022;12:1064537. [PMID: 36704107 DOI: 10.3389/fcimb.2022.1064537] [Reference Citation Analysis]
2 Maurelli M, Gisondi P, Girolomoni G. Tailored biological treatment for patients with moderate-to-severe psoriasis. Expert Rev Clin Immunol 2023;19:37-43. [PMID: 36300752 DOI: 10.1080/1744666X.2023.2141226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Teterina I, Mokricka V, Petrošina E, Pokrotnieks J. Burden of extraintestinal manifestations and comorbidities in treated and untreated ulcerative colitis and Crohn’s disease: a Latvian nationwide prescription database study 2014–2019. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 2022;76:608-617. [DOI: 10.2478/prolas-2022-0094] [Reference Citation Analysis]
4 Sun Y, Li Y, Zhang J. The causal relationship between psoriasis, psoriatic arthritis, and inflammatory bowel diseases. Sci Rep 2022;12:20526. [PMID: 36443384 DOI: 10.1038/s41598-022-24872-5] [Reference Citation Analysis]
5 Di Brizzi EV, Rocco A, Babino G, Buononato D, Argenziano G, Balato A. Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs. Biomedicines 2022;10. [PMID: 36428539 DOI: 10.3390/biomedicines10112968] [Reference Citation Analysis]
6 Freuer D, Linseisen J, Meisinger C. Association Between Inflammatory Bowel Disease and Both Psoriasis and Psoriatic Arthritis: A Bidirectional 2-Sample Mendelian Randomization Study. JAMA Dermatol. [DOI: 10.1001/jamadermatol.2022.3682] [Reference Citation Analysis]
7 Thein D, Egeberg A, Skov L, Loft N. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study. JAMA Dermatol 2022. [PMID: 35767240 DOI: 10.1001/jamadermatol.2022.2360] [Reference Citation Analysis]
8 Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol 2022;13:880201. [PMID: 35757712 DOI: 10.3389/fimmu.2022.880201] [Reference Citation Analysis]
9 Li Y, Guo J, Cao Z, Wu J. Causal Association Between Inflammatory Bowel Disease and Psoriasis: A Two-Sample Bidirectional Mendelian Randomization Study. Front Immunol 2022;13:916645. [PMID: 35757704 DOI: 10.3389/fimmu.2022.916645] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Freuer D, Linseisen J, Meisinger C. Causal links between inflammatory bowel disease and both psoriasis and psoriatic arthritis: a bidirectional two-sample Mendelian randomization study.. [DOI: 10.1101/2022.05.23.22275448] [Reference Citation Analysis]
11 Thye AY, Bah Y, Law JW, Tan LT, He Y, Wong S, Thurairajasingam S, Chan K, Lee L, Letchumanan V. Gut–Skin Axis: Unravelling the Connection between the Gut Microbiome and Psoriasis. Biomedicines 2022;10:1037. [DOI: 10.3390/biomedicines10051037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Sawayama H, Miyamoto Y, Yoshida N, Baba H. Essential updates 2020/2021: Colorectal diseases (benign)—Current topics in the surgical and medical treatment of benign colorectal diseases. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12548] [Reference Citation Analysis]
13 李 露. Psoriasis in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. ACM 2022;12:11555-11568. [DOI: 10.12677/acm.2022.12121666] [Reference Citation Analysis]
14 Bezzio C, Della Corte C, Vernero M, Di Luna I, Manes G, Saibeni S. Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations. Therap Adv Gastroenterol 2022;15:175628482211153. [DOI: 10.1177/17562848221115312] [Reference Citation Analysis]
15 Yan BX, Chen XY, Ye LR, Chen JQ, Zheng M, Man XY. Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction. Front Med (Lausanne) 2021;8:649408. [PMID: 34722555 DOI: 10.3389/fmed.2021.649408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Yang M, Liu W, Deng Q, Liang Z, Wang Q. The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27510. [PMID: 34678884 DOI: 10.1097/MD.0000000000027510] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Maronese CA, Zelin E, Moltrasio C, Genovese G, Marzano AV. Genetic screening in new onset inflammatory bowel disease during anti-interleukin 17 therapy: unmet needs and call for action. Expert Opin Biol Ther 2021;21:1543-6. [PMID: 34448662 DOI: 10.1080/14712598.2021.1974395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Bellinato F, Gisondi P, Girolomoni G. Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis. J Am Acad Dermatol 2021:S0190-9622(21)02212-X. [PMID: 34363908 DOI: 10.1016/j.jaad.2021.07.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hedin CRH, Sonkoly E, Eberhardson M, Ståhle M. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. J Intern Med 2021;290:257-78. [PMID: 33942408 DOI: 10.1111/joim.13282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
20 Hung YT, Le PH, Kuo CJ, Tang YC, Chiou MJ, Chiu CT, Kuo CF, Huang YH. The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. J Clin Med 2021;10:1311. [PMID: 33810197 DOI: 10.3390/jcm10061311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Wu J, Smogorzewski J. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases. Dermatol Ther 2021;34:e14883. [PMID: 33594811 DOI: 10.1111/dth.14883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Jo UH, Lee JY, Lee H, Kim DY, Kang S, Koh SJ, Park H. Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. J Dermatol 2021;48:431-8. [PMID: 33608949 DOI: 10.1111/1346-8138.15676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Kubanov AA, Bogdanova EV. Epidemiology of psoriasis in the Russian Federation according to the patient registry. Vestnik dermatologii i venerologii 2021;98:33-41. [DOI: 10.25208/vdv1268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 D’incan PM. Quoi de neuf en Clinique en 2020 ? Annales de Dermatologie et de Vénéréologie 2020;147:12S1-12S8. [DOI: 10.1016/s0151-9638(20)31101-7] [Reference Citation Analysis]
25 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
26 Conforti C, Dianzani C, Zalaudek I, Cicala M, Persichetti P, Giuffrida R, Morariu S, Neagu N. Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review. Journal of Dermatological Treatment. [DOI: 10.1080/09546634.2020.1836313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Marotto D, Atzeni F, Ardizzone S, Monteleone G, Giorgi V, Sarzi-Puttini P. Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacol Res 2020;161:105206. [PMID: 32998068 DOI: 10.1016/j.phrs.2020.105206] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
28 Woo YR, Park CJ, Kang H, Kim JE. The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic. Int J Mol Sci 2020;21:E7041. [PMID: 32987907 DOI: 10.3390/ijms21197041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
29 Kovitwanichkanont T, Chong AH, Foley P. Beyond skin deep: addressing comorbidities in psoriasis. Med J Aust 2020;212:528-34. [PMID: 32388913 DOI: 10.5694/mja2.50591] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
30 Frew JW. Anti–Saccharomyces cervisiae antibodies in hidradenitis suppurativa: More than a gut feeling. Journal of Allergy and Clinical Immunology 2020;146:458. [DOI: 10.1016/j.jaci.2020.03.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]